DEPARTMENT OF HEALTH & HUMAN SERVICES



SEP 3 0 2010

Food and Drug Administration Rockville MD 20857

Re: Actemra 5,888,510

Docket No. FDA-2010-E-0324

The Honorable David J. Kappos
Undersecretary of Commerce for Intellectual Property
Director of the United States Patent and Trademark Office
Mail Stop Hatch-Waxman PTE
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Director Kappos:

This is in regard to the application for patent term extension for U.S. Patent No. 5,888,510 filed by Chugai Seiyaku Kabushiki Kaisha and Tadamitsu Kishimoto, under 35 U.S.C. § 156. The human biological product claimed by the patent is Actemra 5,888,510 (toclizumab), which was assigned biologics license application (BLA) No. 125276/0.

A review of the Food and Drug Administration's official records indicates that this product was subject to a regulatory review period before its commercial marketing or use, as required under 35 U.S.C. § 156(a)(4). Our records also indicate that it represents the first permitted commercial marketing or use of the product, as defined under 35 U.S.C. § 156(f)(1).

The BLA was approved on January 8, 2010, which makes the submission of the patent term extension application on February 26, 2010, timely within the meaning of 35 U.S.C. § 156(d)(1).

Should you conclude that the subject patent is eligible for patent term extension, please advise us accordingly. As required by 35 U.S.C. § 156(d)(2)(A) we will then determine the applicable regulatory review period, publish the determination in the *Federal Register*, and notify you of our determination.

Please let me know if we can be of further assistance.

Sincerely yours,

Jane A. Axelrad

Associate Director for Policy

Center for Drug Evaluation and Research

cc: Stephen B. Maebius

Foley & Lardner LLP 3000 K Street; N.W.

Washington, DC 20007-5143